Abstract
Musculoskeletal interventions are increasingly used with palliative and curative intent in the multidisciplinary treatment of oncology patients with bone and soft-tissue tumors. There is an unmet need for high-quality evidence to guide broader application and adoption of minimally invasive interventional technologies to treat these patients. Therefore, the Society of Interventional Radiology Foundation and the Society of Interventional Oncology collaborated to convene a research consensus panel to prioritize a research agenda addressing the gaps in the current evidence. This article summarizes the panel's proceedings and recommendations for future basic science and clinical investigation to chart the course for interventional oncology within the musculoskeletal system. Key questions that emerged addressed the effectiveness of ablation within specific patient populations, the effect of combination of ablation with radiotherapy and/or immunotherapy, and the potential of standardization of techniques, including modeling and monitoring, to improve the consistency and predictability of treatment outcomes.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1089.e1-1089.e9 |
| Journal | Journal of Vascular and Interventional Radiology |
| Volume | 32 |
| Issue number | 7 |
| DOIs | |
| State | Published - Jul 2021 |
ASJC Scopus subject areas
- Radiology Nuclear Medicine and imaging
- Cardiology and Cardiovascular Medicine
Access to Document
Other files and links
Fingerprint
Dive into the research topics of 'Musculoskeletal Oncologic Interventions: Proceedings from the Society of Interventional Radiology and Society of Interventional Oncology Research Consensus Panel'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Musculoskeletal Oncologic Interventions : Proceedings from the Society of Interventional Radiology and Society of Interventional Oncology Research Consensus Panel. / Kurup, Anil Nicholas; Jennings, Jack W.; Tutton, Sean et al.
In: Journal of Vascular and Interventional Radiology, Vol. 32, No. 7, 07.2021, p. 1089.e1-1089.e9.Research output: Contribution to journal › Editorial › peer-review
}
TY - JOUR
T1 - Musculoskeletal Oncologic Interventions
T2 - Proceedings from the Society of Interventional Radiology and Society of Interventional Oncology Research Consensus Panel
AU - Kurup, Anil Nicholas
AU - Jennings, Jack W.
AU - Tutton, Sean
AU - Tam, Alda L.
AU - Kelekis, Alexis
AU - Wood, Bradford J.
AU - Dupuy, Damian E.
AU - Napoli, Alessandro
AU - Park, Sean S.
AU - Robinson, Steven I.
AU - Rose, Peter S.
AU - Soulen, Michael C.
AU - White, Sarah B.
AU - Callstrom, Matthew R.
N1 - Funding Information: A.N.K. reports grants from Galil Medical/BTG, Philips, and EDDA Technology and personal fees from UpToDate outside the submitted work. J.W.J. reports personal fees from Stryker, Teleflex Arrow, BD/Bard, and Medtronic during the conduct of the study. S.T. reports personal fees from Stryker, BTG, and Siemens outside the submitted work. A.L.T. reports grants from Boston Scientific and Guerbet and consulting fees from Jounce Therapeutics and Cello Therapeutics outside the submitted work. B.J.W. reports equipment and personnel support for research from Philips during the conduct of the study; nonfinancial support from Philips, Siemens, NVIDIA, Angiodynamics, ArciTrax, and Boston Scientific - Biocompatibles BTG; cooperative research and development agreements with Celsion Corp, Boston Scientific/Biocompatibles BTG, NVIDIA, Siemens, Canon Medical, and XAct Robotics; material transfer agreements or collaboration agreements with Angiodynamics and ArciTrax; shared intellectual property with ArciTrax, NVIDIA, and Philips; and >50 patents available with royalties paid to NIH and Philips, which were supported by the NIH Center for Interventional Oncology and the Intramural Research Program of the National Institutes of Health and the National Cancer Institute, National Institute of Biomedical Imaging and Bioengineering, including NIH Grants Z1A CL040015, 1ZIDBC011242. D.E.D. reports patents from UPtoDate and Springer Verlag, personal fees from Varian outside the submitted work, and has a patent “Thermal accelerant compositions and methods of use” (Patent number: 10722289) licensed to Theromics Inc. and a patent “Percutaneous instruments and materials, construction and methods of use” (Publication number: 20190216537 pending). S.I.R. reports a Robert Wood Johnson Foundation Harold Amos Medical faculty Development Program grant (career development award) and Paul Calabresi Career Development Award for Clinical Oncology (K12) and honoraria to institution from Tracon Pharmaceuticals, BTG Specialty Pharmaceuticals, and GSK and is a consultant to BTG Specialty Pharmaceuticals and a clinical trial site PI for Tracon Pharmaceuticals and GSK. P.S.R. reports prior spine tumor implant design agreement with K2M and prior reimbursement for time and expenses chairing a spine tumor education course (Depuy) and is the Deputy Editor (Oncology) for Journal of the American Academy of Orthopaedic Surgeons. M.C.S. reports grants and personal fees from Guerbet LLC and personal fees from Genetech and Instylla outside the submitted work. S.B.W. reports research support from Guerbet, Siemens, and Insightec, personal fees from Cook, Guerbet, and Penumbra, and grants from Focused Ultrasound Foundation outside the submitted work. M.R.C. reports grants from Galil Medical and personal fees from Medtronic, Boston Scientific, and Johnson and Johnson (Neuwave) outside the submitted work. None of the other authors have identified a conflict of interest. Funding Information: A.N.K. reports grants from Galil Medical / BTG , Philips , and EDDA Technology and personal fees from UpToDate outside the submitted work. J.W.J. reports personal fees from Stryker, Teleflex Arrow, BD/Bard, and Medtronic during the conduct of the study. S.T. reports personal fees from Stryker, BTG, and Siemens outside the submitted work. A.L.T. reports grants from Boston Scientific and Guerbet and consulting fees from Jounce Therapeutics and Cello Therapeutics outside the submitted work. B.J.W. reports equipment and personnel support for research from Philips during the conduct of the study; nonfinancial support from Philips, Siemens , NVIDIA , Angiodynamics , ArciTrax , and Boston Scientific - Biocompatibles BTG; cooperative research and development agreements with Celsion Corp, Boston Scientific/Biocompatibles BTG, NVIDIA, Siemens, Canon Medical, and XAct Robotics; material transfer agreements or collaboration agreements with Angiodynamics and ArciTrax; shared intellectual property with ArciTrax, NVIDIA, and Philips; and >50 patents available with royalties paid to NIH and Philips, which were supported by the NIH Center for Interventional Oncology and the Intramural Research Program of the National Institutes of Health and the National Cancer Institute , National Institute of Biomedical Imaging and Bioengineering , including NIH Grants Z1A CL040015, 1ZIDBC011242. D.E.D. reports patents from UPtoDate and Springer Verlag, personal fees from Varian outside the submitted work, and has a patent “Thermal accelerant compositions and methods of use” (Patent number: 10722289) licensed to Theromics Inc. and a patent “Percutaneous instruments and materials, construction and methods of use” (Publication number: 20190216537 pending). S.I.R. reports a Robert Wood Johnson Foundation Harold Amos Medical faculty Development Program grant (career development award) and Paul Calabresi Career Development Award for Clinical Oncology (K12) and honoraria to institution from Tracon Pharmaceuticals, BTG Specialty Pharmaceuticals, and GSK and is a consultant to BTG Specialty Pharmaceuticals and a clinical trial site PI for Tracon Pharmaceuticals and GSK. P.S.R. reports prior spine tumor implant design agreement with K2M and prior reimbursement for time and expenses chairing a spine tumor education course (Depuy) and is the Deputy Editor (Oncology) for Journal of the American Academy of Orthopaedic Surgeons. M.C.S. reports grants and personal fees from Guerbet LLC and personal fees from Genetech and Instylla outside the submitted work. S.B.W. reports research support from Guerbet, Siemens, and Insightec , personal fees from Cook, Guerbet, and Penumbra, and grants from Focused Ultrasound Foundation outside the submitted work. M.R.C. reports grants from Galil Medical and personal fees from Medtronic, Boston Scientific, and Johnson and Johnson (Neuwave) outside the submitted work. None of the other authors have identified a conflict of interest. Publisher Copyright: © 2021
PY - 2021/7
Y1 - 2021/7
N2 - Musculoskeletal interventions are increasingly used with palliative and curative intent in the multidisciplinary treatment of oncology patients with bone and soft-tissue tumors. There is an unmet need for high-quality evidence to guide broader application and adoption of minimally invasive interventional technologies to treat these patients. Therefore, the Society of Interventional Radiology Foundation and the Society of Interventional Oncology collaborated to convene a research consensus panel to prioritize a research agenda addressing the gaps in the current evidence. This article summarizes the panel's proceedings and recommendations for future basic science and clinical investigation to chart the course for interventional oncology within the musculoskeletal system. Key questions that emerged addressed the effectiveness of ablation within specific patient populations, the effect of combination of ablation with radiotherapy and/or immunotherapy, and the potential of standardization of techniques, including modeling and monitoring, to improve the consistency and predictability of treatment outcomes.
AB - Musculoskeletal interventions are increasingly used with palliative and curative intent in the multidisciplinary treatment of oncology patients with bone and soft-tissue tumors. There is an unmet need for high-quality evidence to guide broader application and adoption of minimally invasive interventional technologies to treat these patients. Therefore, the Society of Interventional Radiology Foundation and the Society of Interventional Oncology collaborated to convene a research consensus panel to prioritize a research agenda addressing the gaps in the current evidence. This article summarizes the panel's proceedings and recommendations for future basic science and clinical investigation to chart the course for interventional oncology within the musculoskeletal system. Key questions that emerged addressed the effectiveness of ablation within specific patient populations, the effect of combination of ablation with radiotherapy and/or immunotherapy, and the potential of standardization of techniques, including modeling and monitoring, to improve the consistency and predictability of treatment outcomes.
UR - http://www.scopus.com/inward/record.url?scp=85108404031&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85108404031&partnerID=8YFLogxK
U2 - 10.1016/j.jvir.2021.04.008
DO - 10.1016/j.jvir.2021.04.008
M3 - Editorial
C2 - 34210477
AN - SCOPUS:85108404031
VL - 32
SP - 1089.e1-1089.e9
JO - Journal of Vascular and Interventional Radiology
JF - Journal of Vascular and Interventional Radiology
SN - 1051-0443
IS - 7
ER -